B. Riley analyst Mayank Mamtani raised the firm’s price target on Checkpoint Therapeutics to $15 from $7 and keeps a Buy rating on the shares. The analyst adjusted the target following the 10:1 reverse split implemented this month and after the announcement of the $7.5M follow-on offering this week. He remains buyers of the stock going into the Biologics License Application filing for cosibelimab expected in January.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CKPT:
- Checkpoint Therapeutics announces $7.5M registered direct offering priced ATM
- Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biotech Alert: Searches spiking for these stocks today
- Checkpoint Therapeutics Announces Reverse Stock Split
- Checkpoint Therapeutics to effect 1-for-10 reverse stock split